Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 26, 2007

Researchers Discover Novel Antitumor Candidates that Also Reverse Drug Resistance

  • Scientists at Duquesne University and the Medical University of South Carolina report discovering novel compounds with  antitumor activity that are also active on drug-resistant cancer cells.

    Delphian Pharmaceuticals, a San Francisco biotech company, has licensed the Duquesne technology. The compounds, like paclitaxol and vincristine, disrupt the tubulin that forms structural supports in the cell necessary for cell extension, migration, and survival, according to the researchers.

    Many tumors develop resistance to chemotherapeutic agents by producing protein pumps such as P-glycoprotein, which expels the anticancer compound. Thus, the level of the drug is reduced, and the cancer cell escapes. The Duquesne compounds, however, are not removed from the tumor cells.

    Unexpectedly, the team also discovered that the Duquesne compounds restored the sensitivity of drug-resistant cancer cells to other anticancer agents by inactivating P-glycoprotein. Compounds with such dual actions, i.e. cytotoxicity and the ability to reverse drug resistance, are unusual, the investigators say.

    The results are reported in the online version of the Journal of Medicinal Chemistry.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »